Skip to main content
SpringerLink
Log in

Treatment of psoriatic arthritis

  • Chapter
  • First Online:
Handbook of Psoriasis and Psoriatic Arthritis

  • 1477 Accesses

Abstract

The primary goal of treating patients with psoriatic arthritis (PsA) is to maximise health-related quality of life (HRQoL), through control of symptoms, prevention of structural damage, and normalization of function and social participation [1]. Treatment goals in PsA should aim at reaching an acceptable disease state as agreed by both patient and physician [2]. In 2009, minimal disease activity (MDA) criteria, the first potential target for treatment in PsA were published.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 59.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 79.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Smolen JS, Braun J, Dougados M, et al. Treating spondylarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis. 2014;73:6-16.

    Google Scholar 

  2. Coates LC, Cook R, Lee KA, et al. Frequency, predictors, and prognosis of sustained minimal disease activity in an observational psoriatic arthritis cohort. Arthritis Care Res (Hoboken). 2010;62:970.

    Google Scholar 

  3. Coates LC, Moverley AR, McParland L, et al. Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial. Lancet. 2015; [Epub ahead of print} doi: 10.1016/S0140-6736(15)00347-5.

    Google Scholar 

  4. Elmamoun M, Ni Mhuircheartaigh O, Kane D, et al. National recommendations for the treatment of psoriatic arthritis. Ir J Med Sci. 2014;184(Suppl 6):Abstract 43 (14A144).

    Google Scholar 

  5. Sarzi-Puttini P, Santandrea S, Boccassini L, et al. The role of NSAIDs in psoriatic arthritis: evidence from a controlled study with nimesulide. Clin Exp Rheumatol. 2001;19:S17-S20.

    Google Scholar 

  6. Kivitz AJ, Espinoza LR, Sherrer YR, Liu-Dumaw M, West CR. A comparison of the efficacy and safety of celecoxib 200 mg and celecoxib 400 mg once daily in treating the signs and symptoms of psoriatic arthritis. Semin Arthritis Rheum. 2007;37:164-173.

    Google Scholar 

  7. Soriano ER, McHugh NJ. Therapies for peripheral joint disease in psoriatic arthritis: a systematic review. J Rheumatol. 2006;33:1422-1430.

    Google Scholar 

  8. Scarpa R, Peluso R, Atteno M, et al. The effectiveness of a traditional therapeutical approach in early psoriatic arthritis: Results of a pilot randomised 6-month trial with methotrexate. Clin Rheumatol. 2008;27:823-826.

    Google Scholar 

  9. Kingsley GH, Kowalczyk A, Taylor H, et al. A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford). 2012; 51:1368-1377.

    Google Scholar 

  10. Kaltwasser JP, Nash P, Gladman D, et al. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo- controlled clinical trial. Arthritis Rheum. 2004;50:1939-1950.

    Google Scholar 

  11. Clegg DO, Reda DJ, Mejias E, et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum. 1996;39:2013-2020.

    Google Scholar 

  12. Fraser AD, van Kuijk AW, Westhovens R, et al. A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis. Ann Rheum Dis. 2005;64:859-864.

    Google Scholar 

  13. Gladman DD, Blake R, Brubacher B, Farewell VT. Chloroquine therapy in psoriatic arthritis. J Rheumatol. 1992;19:1724-1726.

    Google Scholar 

  14. Levy J, Paulus HE, Barnett EV, et al. A double-blind controlled evaluation of azathioprine treatment in rheumatoid arthritis and psoriatic arthritis. Arthritis Rheum.1972;15:116-117.

    Google Scholar 

  15. Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. 2004;50:2264-2272.

    Google Scholar 

  16. Antoni C, Krueger GG, de Vlam K, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis. 2005;64:1150-1157.

    Google Scholar 

  17. Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo controlled trial. Arthritis Rheum. 2005;52:3279-3289.

    Google Scholar 

  18. Kavanaugh A, Mclness I, Mease P, et al. Golimumab, a new human tumor necrosis factor a antibody, administered every 4 weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum. 2009;60:976-986.

    Google Scholar 

  19. Kavanaugh A, McInnes IB, Mease P, et al. Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study). Ann Rheum Dis. 2014;73:1689-1694.

    Google Scholar 

  20. Mease PJ, Fleischmann R, Deodhar AA, et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomized placebo-controlled study (RAPID-PsA). Ann Rheum Dis. 2014;73:48-55.

    Google Scholar 

  21. Mease PJ, Fleischmann RM, Wollenhaupt J, et al. Effect of certolizumab pegol over 48 weeks 0n signs and symptoms in patients with psoriatic arthritis with and without prior tumor necrosis factor inhibitor exposure. Abstract # 312. Arthritis Rheum. 2013;S132.

    Google Scholar 

  22. Van der Heijde D, Fleischmann R, Wollenhaupt J, et al. Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: result of the RAPID-PsA 24-weekphase III double-blind randomised placebo-controlled study of certolizumab pegol. Ann Rheum Dis. 2014;73:233-237.

    Google Scholar 

  23. McInnes IB, Kavanaugh A, Gottlieb AB, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo- controlled PSUMMIT 1 trial. Lancet. 2013;382:780-789.

    Google Scholar 

  24. FitzGerald O. Spondyloarthropathies: apremilast: welcome advance in treatment of psoriatic arthritis. Nat Rev Rheumatol. 2014;10:385-386.

    Google Scholar 

  25. Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. Treatment of psoriatic arthritis in a phase 3 randomized, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis. 2014;73:1020-1026.

    Google Scholar 

  26. Mclnnes IB, Mease PJ, Kirkham B, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double- blind, placebo-controlled, phase 3trial. Lancet. 2015 [Epub ahead of print]; doi:10.1016/S0140-6736(15)61134-5.

    Google Scholar 

  27. Mease PJ, Genovese MC, Greenwald MW, et al. Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. N Engl J Med. 2014;370:2295-2306.

    Google Scholar 

  28. Mease P, Genovese MC, Gladstein G, et al. Abatacept in the treatment of patients with psoriatic arthritis: Results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. Arthritis Rheum. 2011;63:939-948.

    Google Scholar 

  29. Leonardi C, Matheson R, Zachariae C, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic psoriasis. N Engl J Med. 2012;366:1190-1199.

    Google Scholar 

  30. Eli Lilly and Company. A Study of Ixekizumab in Participants With Active Psoriatic Arthritis (SPIRIT-P1). https://clinicaltrials.gov/ct2/show/NCT01695239. Accessed October 15, 2015.

  31. Zangger P, Gladman DD, Bogoch ER. Musculoskeletal surgery in psoriatic arthritis. J Rheumatol. 1998;25:725-729.

    Google Scholar 

  32. Lambert JR, Wright V. Surgery in patients with psoriasis and arthritis. Rheumatol Rehabil. 1979;18:35-37.

    Google Scholar 

  33. Zangger P, Esufali ZH, Gladman DD, et al. Type and outcome of reconstructive surgery for different patterns of psoriatic arthritis. J Rheumatol. 2000;27:967-974.

    Google Scholar 

  34. Hicken GJ, Kitaoka HB, Valente RM. Foot and ankle surgery in patients with psoriasis. Clin Orthop Relat Res. 1994;300:201-206.

    Google Scholar 

  35. Husted JA, Tom BD, Farewell VT, Schentag CT, Gladman DD. A longitudinal study of the effect of disease activity and clinical damage on physical function over the course of psoriatic arthritis: does the effect change over time? Arthritis Rheum. 2007;56:840-849.

    Google Scholar 

  36. Dalal DS, Lin YC, Brennan DM, Borkar N, Korman N, Husni ME. Quantifying harmful effects of psoriatic disease on quality of life: cardio-metabolic outcomes in psoriatic arthritis study (COMPASS). Semin Arthritis Rheum. 2015;44:641-645.

    Google Scholar 

  37. Rosen CF, Mussani F, Chandran V, Eder L, Thavaneswaren A, Gladman DD. Patients with psoriatic arthritis have worse quality of life than those with psoriasis alone. Rheumatology (Oxford). 2012;51:571-576.

    Google Scholar 

  38. Lee S, Mendelsohn A, Sarnes E. The burden of psoriatic arthritis: a literature review from a global health systems perspective. PT. 2010;35:680-689.

    Google Scholar 

  39. Saad AA, Ashcroft DM, Watson KD, et al. Improvement in quality of life and functional status in patients with psoriatic arthritis receiving anti-tumor necrosis factor therapies. Arthritis Care Res (Hoboken). 2010;62:345-353.

    Google Scholar 

  40. Eder L, Jayakar J, Shanmugarajah S, et al. The burden of carotid artery plaques is higher in patients with psoriatic arthritis compared with those with psoriasis alone. Ann Rheum Dis. 2013;72:715-720.

    Google Scholar 

  41. Mok C, Ko G, Ho L, et al. Prevalence of atherosclerotic risk factors and the metabolic syndrome in patients with chronic inflammatory arthritis. Arthritis Care Res. 2011;62:19-202.

    Google Scholar 

  42. Haroon M, Gallagher P, Heffernan E, et al. High prevalence of metabolic syndrome and of insulin resistance in psoriatic arthritis is associated with the severity of underlying disease. J Rheumatol. 2014;41:1357-1365.

    Google Scholar 

  43. Jamnitski A, Symmons D, Peters MJ, et al. Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review. Ann Rheum Dis. 2013;72:211-216.

    Google Scholar 

  44. Peters MJ, Symmons DP, McCarey D, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis. 2010;69:325-331.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The University of Manchester, Manchester, UK

    Musaab Elmamoun & Oliver Fitzgerald

Authors
  1. Musaab Elmamoun
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Oliver Fitzgerald
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Manchester, United Kingdom

    Richard Warren

  2. Montreal, Québec, Canada

    Alan Menter

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Elmamoun, M., Fitzgerald, O. (2016). Treatment of psoriatic arthritis. In: Warren, R., Menter, A. (eds) Handbook of Psoriasis and Psoriatic Arthritis. Adis, Cham. https://doi.org/10.1007/978-3-319-18227-8_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-18227-8_6

  • Published:

  • Publisher Name: Adis, Cham

  • Print ISBN: 978-3-319-18226-1

  • Online ISBN: 978-3-319-18227-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation